Shenzhen New Industries Biomedical Engineering (300832) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 7.97% YoY to ¥3.701bn; net income attributable to shareholders increased 15.42% to ¥1.391bn.

• Adjusted for non-recurring items, 9M net profit increased 16.62% YoY to ¥1.324bn.

Financial highlights

• Q3 revenue was ¥1.280bn, up 3.03% YoY; net profit was ¥522.9m, up 20.55%, and adjusted net profit was ¥499.9m, up 21.98%.

• 9M profit before tax reached ¥1.587bn, up 16.14% YoY; profit excluding FX effects grew 23.42%.

• 9M non-recurring gains totaled ¥66.2m, including ¥61.6m in investment income.

Outlook and guidance

• 230 company-produced and partner automation lines were installed or sold in 9M, supporting progress toward the full-year line installation/sales target.